KBC Group NV Has $45.376 Million Position in Jazz Pharmaceuticals plc – (JAZZ)

KBC Group NV boosted its position in Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 143.1% during the first quarter, Holdings Channel reports. The firm owned 312,661 shares of the specialty pharmaceutical company’s stock after buying an additional 184,046 shares during the period. KBC Group NV’s holdings in Jazz Pharmaceuticals plc – were worth $45,376,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. Partner Investment Management L.P. increased its position in shares of Jazz Pharmaceuticals plc – by 49.5% in the third quarter. Partner Investment Management L.P. now owns 21,391 shares of the specialty pharmaceutical company’s stock worth $2,599,000 after buying an additional 7,082 shares during the period. HBK Investments L P increased its position in shares of Jazz Pharmaceuticals plc – by 186.4% in the third quarter. HBK Investments L P now owns 66,700 shares of the specialty pharmaceutical company’s stock worth $8,103,000 after buying an additional 43,413 shares during the period. Rock Springs Capital Management LP increased its position in shares of Jazz Pharmaceuticals plc – by 4.9% in the third quarter. Rock Springs Capital Management LP now owns 107,000 shares of the specialty pharmaceutical company’s stock worth $12,998,000 after buying an additional 5,000 shares during the period. Avalon Global Asset Management LLC increased its position in shares of Jazz Pharmaceuticals plc – by 22.2% in the third quarter. Avalon Global Asset Management LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock worth $3,341,000 after buying an additional 5,000 shares during the period. Finally, Hsbc Holdings PLC increased its position in shares of Jazz Pharmaceuticals plc – by 24.0% in the third quarter. Hsbc Holdings PLC now owns 8,443 shares of the specialty pharmaceutical company’s stock worth $1,026,000 after buying an additional 1,635 shares during the period. Hedge funds and other institutional investors own 88.56% of the company’s stock.

Institutional Ownership by Quarter for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 0.01% on Friday, reaching $149.15. 261,766 shares of the company’s stock traded hands. The company has a market cap of $8.95 billion, a PE ratio of 22.54 and a beta of 1.22. Jazz Pharmaceuticals plc – has a 12 month low of $95.80 and a 12 month high of $163.75. The firm’s 50 day moving average price is $153.49 and its 200 day moving average price is $128.98.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing the consensus estimate of $1.42 by $0.01. The firm had revenue of $376.10 million for the quarter, compared to analysts’ expectations of $376.58 million. Jazz Pharmaceuticals plc – had a net margin of 24.81% and a return on equity of 30.50%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.26 EPS. On average, equities analysts expect that Jazz Pharmaceuticals plc – will post $11.02 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was posted by Mideast Time and is owned by of Mideast Time. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.mideasttime.com/kbc-group-nv-has-45-376-million-position-in-jazz-pharmaceuticals-plc-jazz/1708881.html.

A number of brokerages have recently issued reports on JAZZ. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals plc – from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Cowen and Company reiterated an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals plc – in a research report on Wednesday, May 10th. Cantor Fitzgerald reiterated a “buy” rating on shares of Jazz Pharmaceuticals plc – in a research report on Thursday, April 27th. Leerink Swann set a $179.00 target price on shares of Jazz Pharmaceuticals plc – and gave the company a “buy” rating in a research report on Thursday, April 27th. Finally, Deutsche Bank AG set a $176.00 target price on shares of Jazz Pharmaceuticals plc – and gave the company a “buy” rating in a research report on Thursday, April 6th. Two research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Jazz Pharmaceuticals plc – has an average rating of “Buy” and an average target price of $183.03.

In other Jazz Pharmaceuticals plc – news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Tuesday, April 11th. The stock was sold at an average price of $152.12, for a total transaction of $152,120.00. Following the completion of the transaction, the chief executive officer now owns 308,491 shares of the company’s stock, valued at $46,927,650.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Paul Treacy sold 884 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $131.97, for a total value of $116,661.48. Following the transaction, the senior vice president now directly owns 18,108 shares of the company’s stock, valued at approximately $2,389,712.76. The disclosure for this sale can be found here. Insiders have sold 50,217 shares of company stock valued at $7,709,933 in the last three months. Insiders own 3.90% of the company’s stock.

About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

12 Month Chart for NASDAQ:JAZZ

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc – (NASDAQ:JAZZ).

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.